ArticleFrontiers in oncology2026
Expanding the spectrum of non-canonical NUT carcinoma: clinicopathological and molecular characterization of
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Nuclear protein in testis (NUT) carcinoma (NC) is an extremely rare and highly aggressive tumor. Non-canonical NC patients frequently have unique clinicopathological characteristics in terms of location, molecular alteration, and outcome, with morphological overlap with other tumors. Here, we report and summarize the non-canonical clinicopathological features of three unusual NC patients harboring Methods: The data of three patients with NC who were diagnosed between 2019 and 2022 at the Department of Pathology at West China Hospital or the Sichuan Kingmed Center for Clinical Laboratory were collected. Immunohistochemistry (IHC), fluorescence Results: All three NC patients were male and aged between 31 and 60 years. The primary sites were the gastric corpus, nasal cavity, and subcutaneous tissue of the calvaria vertex. Histologically, two patients harbored NC with glandular differentiation, and one harbored NC with small cell carcinoma-like morphology. IHC revealed positivity for Pan-CK (cytokeratin) (PCK) (3/3), Epithelial membrane antigen (EMA) (3/3), Cytokeratin 5/6 (CK5/6) (3/3), and P63 (2/3). The Ki-67 index ranged from 20% to 40%. The remaining IHC markers were negative. RNA sequencing revealed Conclusion: In our study, the clinicopathological features of NC in patients with rare molecular alterations are reported and summarized. As increasing numbers of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.